Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-662-8 | CAS number: 1338-24-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1979
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Although no indication that it is a GLP study, the availeble robust study summary published in the "robust study information on reclaimed substances: Naphthenic acid" by the API sufficient detail is provided to make a conclusion about its validity.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Referenceopen allclose all
- Reference Type:
- other: robust study summary
- Title:
- Unnamed
- Year:
- 2 003
- Report date:
- 2003
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 1 979
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- yes
- Remarks:
- This study is a combined study where Accute Dermal Toxicity is considered together with skin irritation.
- Principles of method if other than guideline:
- This study is a combined study where Accute Dermal Toxicity is considered together with skin irritation.
- GLP compliance:
- not specified
- Test type:
- standard acute method
- Limit test:
- yes
Test material
- Reference substance name:
- Naphthenic acids
- EC Number:
- 215-662-8
- EC Name:
- Naphthenic acids
- Cas Number:
- 1338-24-5
- Molecular formula:
- For the acidic (naphthenic) fraction: CnH2n+zO2, where n = carbon number and z = homologous group series number: z = 0 when no ring structures are present, z = -2 when 1 ring is present, z = -4 when 2 rings are present etc. For the non-acidic fraction: not applicable
- IUPAC Name:
- 11-(decahydronaphthalen-2-yl)undecanoic acid; 11-cyclopentylundecanoic acid; 15-cyclohexylpentadecanoic acid; 3-(tetradecahydroanthracen-2-yl)propanoic acid; 4-(tetradecahydroanthracen-2-yl)butanoic acid; 7-(tetradecahydroanthracen-2-yl)heptanoic acid; 9-(octahydropentalen-2-yl)nonanoic acid; dodecahydro-1H-phenalene-1-carboxylic acid
- Test material form:
- liquid
- Details on test material:
- Physical state: Viscous liquid
Appearance: Pale yellow to dark amber
Constituent 1
Test animals
- Species:
- rabbit
- Strain:
- New Zealand White
- Sex:
- male/female
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- 3.16 g/kg naphthenic acid was applied dermally to the clipped abraded abdomens of each animal. The area was covered with gauze and secured by a thick plastic binder, which was removed atfter 24 hours, and the skin washed with water or corn oil.
- Duration of exposure:
- 24 hours
- Doses:
- 3.16 g/kg naphthenic acid was applied dermally to the clipped abraded abdomens of each animal
- No. of animals per sex per dose:
- 2 per sex
- Control animals:
- not specified
- Details on study design:
- According to experimental protocol, if no deaths occurred at the initial level, no addition animals were dosed. If one animal died, the experiment was to be repeated using 3 more groups of animals dosed at varying levels.
Following the skin wash, animals were observed for mortality and toxic effects at 2 hr and 4 hr, and once daily thereatter. Body weights were recorded pretest and at termination. Dermal irritation was recorded at 24 hr, 3, 7, 10 and 14 days.
The rabbits were observed 1, 2, 4 and 6 hours after dosing and once daily for 14 days. Mortality, toxicity and pharmacological effects were recorded. Body weights were recorded pretest and in the survivors at 14 days. At 14 days the survivors were sacrificed. Ananimals were examined for gross pathology.
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- approximate LD50
- Effect level:
- > 3 160 mg/kg bw
- Based on:
- test mat.
- Mortality:
- no
- Clinical signs:
- other: lethargy, diarrhea, ptosis, adipsia, anorexia, and few feces
- Gross pathology:
- No
- Other findings:
- No deaths occurred at the 3.16 mg/kg dose level. Most of the animals (3/4) appeared normal during the first 2 to 4 hours of dosing, after which symptoms of toxicity were observed. 3 out of 4 animals (1 male, 2 female) showed signs of toxicity until day 12 or 13. During the first 5 days, all animals displayed one or more of the following symptoms: lethargy, diarrhea, ptosis, adipsia, anorexia, and few feces.
The LD50 was determined to be greater than 3.16 g/kg bw
Redness and irritation scores were recorded at 24 hr, 3, 7, 10 and 14 days post-washing. 4 Hour occluded sites (DOT, OECD methods)
Mean values (24, 48 & 72 hours) for erythema and edema at the intact sites were 1.69 and 1.3 respectively. The initial response of the skin to the test material was slight, with little difference in response between intact or abraded sites.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Executive summary:
New Zealand white rabbits were dermally treated with 3.16 g/kg Naphthenic acids under occlusive dressing for 24 hours, afeter which the skin was washed with water or corn oil. The rabbits were observed 1, 2, 4 and 6 hours after dosing and once daily for 14 days. No deaths occurred at the 3.16 mg/kg dose level. Most of the animals (3/4) appeared normal during the first 2 to 4 hours of dosing, after which symptoms of toxicity were observed. 3 out of 4 animals (1 male, 2 female) showed signs of toxicity until day 12 or 13. During the first 5 days, all animals displayed one or more of the following symptoms: lethargy, diarrhea, ptosis, adipsia, anorexia, and few feces.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
